Company Overview and News

2
SBI, HPCL, IOC, Cipla, Dr Reddy’s, Bosch results

2018-05-21 thehindubusinessline
Close to 60 companies including Andhra Bank, Allcargo, Bata India, Batliboi, Ballarpur, Bemco Hydraulics, Bosch, Bharat Forge, Capital Trust, CARE, Cipla, Dr Reddy’s Laboratories, GE Power, Future Consumer, HPCL, Igarashi Motors, IOC, Jamna Auto, L&T Technology, Minda Industries, SBI, Sonata Soft, Sundaram Clayton, Symphony, TVS Srichakra, Triveni Turbine and VIP Industries will declare their quarterly and full-year results for the period ended March 2018 on Tuesday.
TRITURBINE ENKEIWHEL 500008 BEMHY MINDAIND 532539 532418 533477 ARJQY AMARAJABAT 533655 BATAINDIA TVSSRICHAK 511505 CAPITALT 509243 522650 500493 500043 BHARATFORG ANDHRABANK

0
TVS Srichakra Limited - Trading Window

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

3
These 20 evergreen companies rising star stocks are your best bet to make a multibagger portfolio

2018-04-27 moneycontrol
Return-hungry investors are always on the lookout for stocks that can offer value and at the same time promise future growth which remains elusive in most of the companies that have rallied in the past year.
500825 519552 532809 FNXBY AVANTI FSL BRTQY 512573 519600 CCL PIDILITIND TVSSRICHAK PDLTY HERITGFOOD 509243 FINCABLES BRITANNIA 500331 500144

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

0
Tyre stocks rally: Balkrishna Ind jumps 6%, MRF hits record high, Apollo Tyres hits 52-week high

2018-04-03 moneycontrol
Despite the Indian equity market trading almost flat on Tuesday afternoon with the Nifty shedding 8 points at 10,203 mark and the Sensex was down 15 points or 0.05 percent, tyre stocks were in focus with MRF jumping 3.47 percent and hitting a record high of Rs 75,612 per scrip on the NSE.
BALKRISIND TVSSRICHAK 500877 APOLLOTYRE 509243 AYRQY 502355

0
Tyre stocks gain on falling rubber prices

2018-04-03 thehindubusinessline
Tyre stocks gained on falling rubber prices. Shares of tyre makers Apollo Tyres Ltd and TVS Srichakra Ltd were up over 2 per cent each in the morning trade.
TVSSRICHAK 500877 APOLLOTYRE 509243 AYRQY

0
TVS Srichakra Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TVSSRICHAK 509243

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...